Hirose T - Search Results

1

Delayed elimination of SN-38 in cancer patients with severe renal failure.

Fujita K, Sunakawa Y, Miwa K, Akiyama Y, Sugiyama M, Kawara K, Ishida H, Yamashita K, Mizuno K, Saji S, Ichikawa W, Yamamoto W, Nagashima F, Miya T, Narabayashi M, Ando Y, Hirose T, Sasaki Y. Fujita K, et al. Among authors: hirose t. Drug Metab Dispos. 2011 Feb;39(2):161-4. doi: 10.1124/dmd.110.035451. Epub 2010 Oct 27. Drug Metab Dispos. 2011. PMID: 20980446 Clinical Trial.

2

Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.

Hirose T, Horichi N, Ohmori T, Ogura K, Hosaka T, Ando K, Ishida H, Noguchi H, Adachi M. Hirose T, et al. Lung Cancer. 2003 Jun;40(3):333-8. doi: 10.1016/s0169-5002(03)00075-8. Lung Cancer. 2003. PMID: 12781433 Clinical Trial.

3

Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.

Hirose T, Shirai T, Ishida H, Ando K, Sugiyama T, Kusumoto S, Hosaka T, Nakashima M, Ohmori T, Adachi M. Hirose T, et al. Cancer Chemother Pharmacol. 2007 Jul;60(2):267-74. doi: 10.1007/s00280-006-0369-4. Epub 2007 Feb 2. Cancer Chemother Pharmacol. 2007. PMID: 17273827 Clinical Trial.

4

Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer.

Fujita K, Ando Y, Yamamoto W, Miya T, Endo H, Sunakawa Y, Araki K, Kodama K, Nagashima F, Ichikawa W, Narabayashi M, Akiyama Y, Kawara K, Shiomi M, Ogata H, Iwasa H, Okazaki Y, Hirose T, Sasaki Y. Fujita K, et al. Among authors: hirose t. Cancer Chemother Pharmacol. 2010 Jan;65(2):251-8. doi: 10.1007/s00280-009-1029-2. Cancer Chemother Pharmacol. 2010. PMID: 19466410

5

Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.

Hirose T, Fujita K, Nishimura K, Ishida H, Yamashita K, Sunakawa Y, Mizuno K, Miwa K, Nagashima F, Tanigawara Y, Adachi M, Sasaki Y. Hirose T, et al. Oncol Rep. 2010 Aug;24(2):529-36. doi: 10.3892/or_00000889. Oncol Rep. 2010. PMID: 20596643 Clinical Trial.

6

UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.

Sunakawa Y, Ichikawa W, Fujita K, Nagashima F, Ishida H, Yamashita K, Mizuno K, Miwa K, Kawara K, Akiyama Y, Araki K, Yamamoto W, Miya T, Narabayashi M, Ando Y, Hirose T, Saji S, Sasaki Y. Sunakawa Y, et al. Among authors: hirose t. Cancer Chemother Pharmacol. 2011 Aug;68(2):279-84. doi: 10.1007/s00280-010-1485-8. Epub 2010 Oct 19. Cancer Chemother Pharmacol. 2011. PMID: 20957480

7

Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer.

Hirose T, Murata Y, Oki Y, Sugiyama T, Kusumoto S, Ishida H, Shirai T, Nakashima M, Yamaoka T, Okuda K, Ohnishi T, Ohmori T. Hirose T, et al. Oncol Res. 2012;20(2-3):131-7. doi: 10.3727/096504012x13473664562583. Oncol Res. 2012. PMID: 23193919

8

High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer.

Fujita K, Hirose T, Kusumoto S, Sugiyama T, Shirai T, Nakashima M, Akiyama Y, Sasaki Y. Fujita K, et al. Among authors: hirose t. Lung Cancer. 2014 Oct;86(1):113-4. doi: 10.1016/j.lungcan.2014.07.021. Epub 2014 Aug 2. Lung Cancer. 2014. PMID: 25123334 No abstract available.

9

Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.

Hirose T, Fujita K, Kusumoto S, Oki Y, Murata Y, Sugiyama T, Ishida H, Shirai T, Nakashima M, Yamaoka T, Okuda K, Ohmori T, Sasaki Y. Hirose T, et al. Lung Cancer. 2016 Mar;93:69-76. doi: 10.1016/j.lungcan.2016.01.005. Epub 2016 Jan 11. Lung Cancer. 2016. PMID: 26898617

10

Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.

Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Yamaoka T, et al. Among authors: hirose t. Mol Cancer Ther. 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. Epub 2016 Sep 9. Mol Cancer Ther. 2016. PMID: 27612490

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,745 results

Search Page

Filters